Q32 Bio Inc. is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases. It focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7RÎą), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). It has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļQTTB
āļāļ·āđāļāļāļĢāļīāļĐāļąāļQ32 Bio Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMar 28, 2018
āļāļĩāļāļĩāđāļMorrison (Jodie Pope)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ42
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļMar 28
āļāļĩāđāļāļĒāļđāđ830 Winter Street
āđāļĄāļ·āļāļWALTHAM
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ02451
āđāļāļĢāļĻāļąāļāļāđ17819990232
āđāļ§āđāļāđāļāļāđhttps://www.q32bio.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļQTTB
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMar 28, 2018
āļāļĩāļāļĩāđāļMorrison (Jodie Pope)
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
Dr. Isaac Manke, Ph.D.
Independent Director
Dr. Isaac Manke, Ph.D.
Independent Director
Dr. Isaac Manke, Ph.D.
Independent Director
Ms. Mary T. Thistle, CPA
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research